Prof Julien Taieb treats BRAFV600E-mutant mCRC with encorafenib + cetuximab
Professor Julien Taieb of Georges Pompidou European Hospital in Paris, France, shares a case of a 58-year-old female diagnosed with BRAFV600E-mutant colorectal cancer, whose disease progressed and became metastatic following FOLFOX. Subsequent treatment with pembrolizumab was not tolerated well and the patient was switched to encorafenib plus cetuximab, which led to improvement in patient’s general condition and allowed cytoreductive surgery followed by complete tumour regression.
